Centralized Multidisciplinary Retinoblastoma Care: Closing Outcome Gaps in Resource-Limited Settings with Telemedicine and Advanced Globe Salvage
Posted inClinical Updates news Oncology Ophthalmology

Centralized Multidisciplinary Retinoblastoma Care: Closing Outcome Gaps in Resource-Limited Settings with Telemedicine and Advanced Globe Salvage

Centralized multidisciplinary retinoblastoma care incorporating telemedicine and international partnership at KHCC improved survival and globe salvage rates to levels comparable with high-income countries, demonstrating a scalable model for reducing global disparities over two decades.
Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights
Posted inClinical Updates news Oncology

Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights

This review synthesizes current evidence comparing patient-perceived quality of shared decision-making (SDM) for lung cancer screening (LCS) delivered via telehealth versus in-person encounters, highlighting comparable outcomes and implications for equitable access.
Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib
Posted inGeneral Surgery news Oncology

Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib

This study compares radiographic versus pathology-integrated response metrics to identify optimal surgical timing after neoadjuvant imatinib treatment in KIT exon 11-mutant gastrointestinal stromal tumors (GIST). Pathology measures indicate a later window of near-maximal treatment effect than radiographic analysis.
Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up
Posted innews OB/GYN & Women’s Health Oncology

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients with KRAS mutations.